MNGI Digestive Health phone: 651-273-1033 email: Allison.Jentges@mngi.com

C. difficile infection keeps us apart.

New research brings us closer together.

Now Enrolling at MNGI Digestive Health in Plymouth, Minnesota: The CDI-SCOPE study for adults with recurrent C. difficile infection (CDI).

If you are eligible and decide to participate:

  • There is no placebo
  • Study sponsor covers costs of the study drug and participation
  • You will receive the study drug by colonoscopy
CLICK HERE TO CONTACT US
CDI SCOPE Clinical Trial

This clinical study tests an FDA-approved study drug when given by colonoscopy

CDI-SCOPE is a clinical study that investigates RBX2660 to find out if it can prevent recurrence of your CDI when administered through a colonoscopy.

The study drug, RBX2660, is approved by the US Food and Drug Administration (FDA), and marketed in the United States as REBYOTA™ (fecal microbiota, live – jslm)1 for rectal administration only.

Study doctors want to find out if RBX2660 is also effective in preventing CDI recurrence when given by colonoscopy.

CDI-SCOPE Clostridioides difficile trial

There is no placebo and you may be compensated for your time and travel

Study patients receive expert medical care and specialized attention from the study team. There is no placebo drug given and you do not have to pay for the study drug, supplies, procedures, or tests that are part of the study.

Your participation will help us understand more about RBX2660 in people with recurrent CDI.

If you or someone you know has a C. difficile infection, contact Allison Jentges at MNGI Digestive Health to learn more.

Call or E-mail to Find Out if You Qualify to Participate:
Name: Allison Jentges, Clinical Research Coordinator
Phone: 651-273-1033
E-mail: Allison.Jentges@mngi.com

CDI-SCOPE c diff clinical trial

To learn more about participating in the CDI-SCOPE clinical study

CLICK HERE TO CONTACT US

How to Participate in This Study

To be eligible, you must be:

  • At least 18 years old
  • Diagnosed with recurrent CDI
  • Able to give informed consent

This is not a complete list of study requirements. The clinical study team will review the complete requirements with you and determine if you are eligible to participate in the clinical study.

If it is determined you may be a candidate for the CDI-SCOPE study, you will:

  • Be asked to visit the clinical site if you are interested in participating
  • Receive detailed information regarding the clinical study, the risks and benefits of participating, and your responsibilities as a participant
  • Have time for your questions to be answered, and talk about the study with others (your doctor, family and friends)
  • If you are confirmed to be a candidate and decide to participate, you may be compensated for completing required study visits and phone calls

To see if you may qualify for the CDI-SCOPE clinical study

CLICK HERE TO CONTACT US

Frequently Asked Questions

What is a clinical study?

In a clinical study like this one, participants receive a study drug to find out if it is effective, and whether or not it has side effects.

What is a study drug?

A study drug is a substance that is being tested in clinical studies. The study is reviewed by an ethics committee that approves testing the study drug in people.

Why is this study important?

Individuals with recurrent CDI can suffer from repeated episodes of severe diarrhea and other difficult symptoms that not only interrupt day-to-day activities but can create a serious burden on life. Many people with this condition are successfully treated with antibiotics, but these can cause even more disruption to the gut. Unfortunately, this disruption can sometimes lead to additional CDI episodes when the antibiotics are stopped.

This study is evaluating a United States Food and Drug Administration (FDA) approved study drug called RBX2660 (REBYOTA) to find out how it works when administered through a colonoscopy. Pharmaceutical companies use clinical studies like this one to learn more about study drugs before and after they are made available to the public. Study participants can help us in this important research.

Why should I take part in this study?

Participation in a clinical trial is voluntary. Clinical studies are important for medical advances. Current treatments for diseases have only become available because individuals agreed to participate in clinical studies.

Thank you for considering participation in this study.

CLICK HERE TO CONTACT US
1. US Food and Drug Administration. FDA Approves First Fecal Microbiota Product. https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product. Accessed December 1, 2022.
×

The CDI-SCOPE clinical study is open for adults with recurrent C. difficile infection that is only controlled by taking antibiotics.

To speak with the clinical research coordinator at a study site in your area, please provide the following information:

Contact Us
How may we assist you?
I prefer to be contacted by: